THERMO FISHER SCIENTIFIC POWDER US HOLDINGS LIMITED
Get an alert when THERMO FISHER SCIENTIFIC POWDER US HOLDINGS LIMITED files next
Leroy will email you the moment a new filing lands at Companies House — one short note per filing, nothing else.
Next accounts due
2026-09-30 (in 4mo)
Last filed for 2024-12-31
Confirmation statement due
2026-11-04 (in 6mo)
Last made up 2025-10-21
Watchouts
None on the register
Cash
—
Latest balance sheet
Net assets
£3B
-77.3% vs 2023
Employees
—
Average over period
Profit before tax
£732M
+226.8% vs 2023
Net assets
2-year trend · vs Unclassified median
Accounts
2-year trend · latest reflected 2024-12-31
| Metric | Trend | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Turnover | — | — | |
| Operating profit | -£12,602 | -£19,878,862,120 | |
| Profit before tax | -£577,791,698 | £732,353,595 | |
| Net profit | -£577,791,698 | £732,353,595 | |
| Cash | — | — | |
| Total assets less current liabilities | £25,630,251,297 | £10,468,360,267 | |
| Net assets | £15,298,954,040 | £3,472,867,309 | |
| Equity | £15,298,954,040 | £3,472,867,309 | |
| Average employees | — | — | |
| Wages | — | — |
Values shown as filed in the company's annual accounts. — indicates the figure wasn't present under that line item in that period. About these numbers
Ratios
Computed from the line items above — sparklines read oldest → newest
| Ratio | Trend | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Return on capital employed | -0.0% | -189.9% | |
| Current ratio | 0.00x | 0.00x | |
| Interest cover | -0.00x | -30.73x |
Margins divide P&L lines by turnover. Gearing is liabilities over total assets. Current ratio is current assets over creditors falling due within one year. Interest cover is operating profit over absolute finance costs. Sector-distribution context coming next.
Audit & accounting basis
- Accounting basis
- FRS 102
- Reporting scope
- Standalone (parent only)
- Auditor
- Mitchell Charlesworth (Audit) Limited
- Audit opinion
- Unqualified (clean)
- Going concern
- Affirmed
“In auditing the financial statements, we have concluded that the directors' use of the going concern basis of accounting in the preparation of the financial statements is appropriate. Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the company's ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue.”
Group structure
- THERMO FISHER SCIENTIFIC POWDER US HOLDINGS LIMITED · parent
- Wildcat Acquisition Holdings (UK) Limited 100%
- Thermo Fisher Scientific Powder US Limited 100%
- Thermo Fisher Scientific PN3 LLC 100%
- Thermo Fisher Scientific Powder US Holdings LLC 100%
- PPD International Holdings (UK) Ltd 100%
- PPD International Holdings, LLC 100%
- Clinical Technology Centre (International) Limited 100%
- Clinical Technology Centre (Ireland) Limited 100%
- Excel PharmaStudies, Inc. 100%
- Greenbird Limited 100%
- Limited Liability Company Contract Research Organisation Innopharm - Ukraine 100%
- Limited Liability Company PPD Development (Smolensk) 100%
- LLC PPD Ukraine 100%
- Medical Centre Synexus Sofia EOOD 100%
- Medimix Latam Pesquisa de Mercado Ltda 100%
- Pharmaceutical Product Development OÜ 100%
- Pharmaceutical Product Development South Africa (Proprietary) Limited 100%
- Pharmaceutical Product Development South Africa (Proprietary) Limited - Uganda Branch 100%
- Pharmaceutical Product Development Spain SL 99.24%
- PPD (Netherlands) B.V. 100%
- PPD (Netherlands) LLC 100%
- PPD Argentina S.A. 95%
- PPD Australia Pty Limited 100%
- PPD Bulgaria EOOD 100%
- PPD Canada, Ltd. 100%
- PPD Colombia S.A.S 100%
- PPD CT Investments LLP 20%
- PPD Czech Republic S.R.O. 100%
- PPD Denmark, Filial af PPD Scandinavia AB, Sverige 100%
- PPD Development (HK) Limited 50%
- PPD Development (HK) Limited - Taiwan Branch 100%
- PPD Development (S) Pte. Ltd - Indonesia 100%
- PPD Development (S) Pte. Ltd. 100%
- PPD Development (S) Pte. Ltd. - Malaysia branch 100%
- PPD Development (S) Pte. Ltd. Philippines Branch 100%
- PPD Development (S) Pte. Ltd. Korea Branch 100%
- PPD Development (Thailand) Co., Ltd 100%
- PPD Development Ireland Limited 100%
- PPD do Brasil- Suporte a Pesquisa Clinica Ltda. 100%
- PPD France SAS 100%
- PPD Georgia LLC 100%
- PPD Germany GmbH 100%
- PPD Germany GmbH & Co. KG 100%
- PPD Global Central Labs (S) Pte. Ltd. 100%
- PPD Global Limited - Ghana Branch 100%
- PPD Global Limited Merkezi Ingiltere Turkiye Istanbul Subesi 100%
- PPD Global Ltd - Austria Branch 100%
- PPD Global Ltd - Greece Branch 100%
- PPD Global Ltd. 100%
- PPD Hrvatska d.o.o. 100%
- PPD International Holdings GmbH 100%
- PPD International Holdings, Inc. y Compania Limitada 99%
- PPD International Investments Limited 100%
- PPD Italy S.r.l 100%
- PPD Latvia SIA 100%
- PPD Magyarország Kutatási és Fejlesztési Kft 100%
- PPD Mexico S.A. de C.V. 100%
- PPD Netherlands International LLC 100%
- PPD Panama, S. DE. R.L. 100%
- PPD Peru S.A.C. 100%
- PPD Pharmaceutical Development (Beijing) Co., Ltd Wuhan Branch 100%
- PPD Pharmaceutical Development (Beijing) Co., Ltd. 100%
- PPD Pharmaceutical Development (Beijing) Co., Ltd. Guangzhou Branch 100%
- PPD Pharmaceutical Development (Beijing) Co., Ltd. Shanghai Branch 100%
- PPD Pharmaceutical Development (Beijing) Co., Ltd. Shenyang Branch 100%
- PPD Pharmaceutical Development India Private Limited 100%
- PPD Pharmaceutical Development Japan K.K. 100%
- PPD Pharmaceutical Development Philippines Corp. 100%
- PPD Pharmaceutical Development Vietnam Company Limited 100%
- PPD Poland sp. z o.o. 100%
- PPD Research Pharmaceutical Product Development, LLC 100%
- PPD Romania SRL 100%
- PPD Scandinavia AB 100%
- PPD Scandinavia AB (Norway Branch) 100%
- PPD Serbia D.O.O. Beograd 100%
- PPD Slovak Republic s.r.o. 100%
- PPD UK Holdings Limited 100%
- PPD-SNBL K.K. 60%
- Shorecloud Corporation 99.98%
- Synexus Bulgaria EOOD 100%
- Synexus Clinical Research Acquisitions Limited 100%
- Synexus Clinical Research GmbH 100%
- Synexus Clinical Research Limited 100%
- Synexus Clinical Research Midco No1 Limited 100%
- Synexus Clinical Research South Africa (Pty) Limited 100%
- Synexus Czech s.r.o. 100%
- Synexus Limited 100%
- SYNEXUS Magyarország Egészségügyi Szolgáltató Korlátolt Felelősségű Társaság 100%
- Synexus Polska sp. z o.o. 100%
- Synexus Ukraine Limited Liability Company 100%
- The Resident Representative Office of PPD Development (S) Pte. Ltd. in Ho Chi Minh City 100%
- Thermo Fisher Scientific BLG Limited 100%
Significant events
- “In the year, the company paid a cash dividend during the year which amounted to $23,433,608,000”
- “On 15 September 2024, Thermo Fisher Scientific Powder UK Senior Holdings Limited and the company enter into an agreement to offset their liabilities under the intercompany receivable against 2 loans which leads to creation of a share premium ($1,103,140).”
- “On 15 September 2024, Thermo Fisher Scientific Powder UK Senior Holdings Limited contributes Thermo Fisher Scientific Powder US Limited and $305,000,000 to Thermo Fisher Scientific Powder US Holdings Limited in exchange for 1 ordinary share ($1,000) and share premium ($6,491,167,432).”
- “On 4 December 2024, the company converts its entire share premium into distributable reserve.”
Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers
People
6 active · 2 resigned
| Name | Role | Appointed | Born | Nationality |
|---|---|---|---|---|
| OAKWOOD CORPORATE SECRETARY LIMITED | Corporate Secretary | 2021-10-22 | — | — |
| AHMED, Syed Waqas | Director | 2021-10-22 | Nov 1979 | British |
| CAMERON, Euan Daney Ross | Director | 2021-10-22 | Mar 1976 | British |
| GREEN, Georgina Adams | Director | 2024-04-18 | Mar 1970 | British |
| SMITH, Anthony Hugh | Director | 2021-10-22 | May 1962 | American |
| STARR, Alison Jane | Director | 2024-04-18 | Jan 1977 | British |
Show 2 resigned officers
| Name | Role | Appointed | Resigned |
|---|---|---|---|
| GREGG, Rhona | Secretary | 2021-10-22 | 2026-03-31 |
| NORMAN, David John | Director | 2021-10-22 | 2024-04-18 |
Ownership
Persons with significant control
| Name | Kind | Nature of control | Notified | Status |
|---|---|---|---|---|
| Thermo Fisher Scientific Powder Uk Senior Holdings Limited | Corporate entity | Shares 75–100%, Voting 75–100%, Appoints directors | 2023-11-17 | Active |
| Thermo Fisher Scientific Inc. | Corporate entity | Shares 75–100%, Voting 75–100%, Appoints directors | 2021-10-22 | Ceased 2023-11-17 |
Filing timeline
Last 20 of 45 total filings
Material constitutional events — rename, articles re-file, resolution
- 2024-12-09 RESOLUTIONS Resolution
| Date | Type | Category | Description | |
|---|---|---|---|---|
| 2026-04-01 | TM02 | officers | Termination secretary company with name termination date | |
| 2026-02-16 | SH01 | capital | Capital allotment shares | |
| 2025-10-30 | CS01 | confirmation-statement | Confirmation statement with no updates | |
| 2025-06-09 | AA | accounts | Accounts with accounts type full | |
| 2024-12-09 | SH20 | capital | Legacy | |
| 2024-12-09 | SH19 | capital | Capital statement capital company with date currency figure | |
| 2024-12-09 | CAP-SS | insolvency | Legacy | |
| 2024-12-09 | RESOLUTIONS | resolution | Resolution | |
| 2024-11-06 | CS01 | confirmation-statement | Confirmation statement with updates | |
| 2024-11-05 | SH01 | capital | Capital allotment shares | |
| 2024-06-07 | AA | accounts | Accounts with accounts type full | |
| 2024-04-23 | AP01 | officers | Appoint person director company with name date | |
| 2024-04-19 | AP01 | officers | Appoint person director company with name date | |
| 2024-04-19 | TM01 | officers | Termination director company with name termination date | |
| 2024-03-06 | SH01 | capital | Capital allotment shares | |
| 2024-02-08 | PSC02 | persons-with-significant-control | Notification of a person with significant control | |
| 2024-02-08 | PSC07 | persons-with-significant-control | Cessation of a person with significant control | |
| 2023-12-07 | SH01 | capital | Capital allotment shares | |
| 2023-10-23 | CS01 | confirmation-statement | Confirmation statement with updates | |
| 2023-09-11 | SH01 | capital | Capital allotment shares |
Public-record activity
Raw counts from Companies House — last 12–24 months
- Filings
- 4
- Capital events
- 4
- Officers appointed
- 0
- Officers resigned
- 1
last 12 months
last 24 months
last 12 months
last 12 months
Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.
Year-on-year
FY2023 → FY2024 · period ending 2024-12-31 vs 2023-12-31
-
Turnover
—
Not reported
-
Cash
—
Not reported
-
Net assets
-77.3%
£15,298,954,040 £3,472,867,309
-
Employees
—
Not reported
-
Operating profit
-157,743,608.3%
-£12,602 -£19,878,862,120
-
Profit before tax
+226.8%
-£577,791,698 £732,353,595
Each % is (latest − prior) ÷ |prior| for the line item as filed. The comparison is only shown when the latest and prior accounts cover broadly equal-length periods — short or long stubs (typical around incorporation or a year-end change) are suppressed rather than misrepresented. Lines a company doesn't report are omitted. About these numbers